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Abstract
HDR syndrome is a rare autosomal dominant disorder caused by mutations in the GATA3 gene and characterized by
hypoparathyroidism, sensorineural deafness and renal abnormalities. Here we report a Brazilian family, from which
the proband, his mother and his grandfather were diagnosed with bilateral sensorineural hearing loss. Molecular
screening of the GJB2, GJB6 and MTRNR1 genes in the proband showed no alterations; however, whole exome se-
quencing detected a heterozygous mutation, c.1099C > T (p.Arg367*), in the GATA3 gene. Segregation analyses
showed that the mother also had the mutation, but not the grandparents, hence indicating a different hearing impair-
ment type for the grandfather. Paternity test of the mother of the proband confirmed that she has a de novo mutation.
Furthermore, HDR syndrome was confirmed with new clinical evaluations showing right kidney agenesis in the
proband. This is the first study reporting only deafness and renal abnormalities as symptoms of the p.Arg367* muta-
tion in the GATA3 gene, and also the sixth HDR syndrome case in the world, and the first on the American continent.
Together with other reported cases, this study highlights the variability of HDR syndrome symptoms in individuals
with the p.Arg367* mutation, emphasizing the importance of molecular analyses for correct diagnosis.
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The Barakat Syndrome, also known as HDR syn-
drome (OMIM 146255), is a very rare disorder associated
with an autosomal dominant inheritance pattern and a com-
bination of symptoms, such as hypoparathyroidism, senso-
rineural deafness and/or renal abnormalities (Barakat et al.,
1977; Bilous et al., 1992; Hasegawa et al., 1997; Van
Beelen et al., 2014). Among the clinical manifestations,
congenital and bilateral sensorineural deafness is the most
consistent symptom, ranging from moderate to severe, es-
pecially at higher frequencies (Van Beelen et al., 2014). On
the other hand, hypoparathyroidism can range from symp-
tomatic or asymptomatic hypocalcemia with low or unde-
tectable parathyroid hormone (PTH) serum levels to
paresthesias (Van Esch et al., 2000), while also renal abnor-
malities present an incomplete penetrance that includes re-
nal dysplasia, hypoplasia, aplasia and vesico-ureteric reflux
in one or both kidneys. Importantly, the presence, severity
and onset age of the three clinical manifestations can vary
among the affected individuals (Van Esch et al., 2000).
Although the reasons for the heterogeneous pheno-
types still remain unclear, the HDR syndrome itself has
been shown to be caused by alterations that lead to GATA3
haploinsufficiency (Hasegawa et al., 1997; Van Esch et al.,
2000; Muroya et al., 2001; Nesbit et al., 2004; Ferraris et
al., 2009; Ohta et al., 2011; Stenson et al., 2017). This gene
has six exons and is expressed during embryonic stages
(Debacker et al., 1999), generating two isoforms: one with
444 residues (NM_001002295.1) and another with 443 res-
idues (NM_002051.2), of which the latter is considered as
the canonical isoform (Uniprot P23771-1). The GATA3
protein is classified as a transcription factor constituted by
two transactivating domains (TA1 and TA2) and two
highly conserved zinc finger domains: a C-terminal zinc
finger (ZnF2), which is essential for DNA binding, and an
N-terminal zinc finger (ZnF1) that helps to stabilize the
DNA binding, while also interacting with another multi-
type zinc finger protein known as Friends of GATA (FOG)
(Yang et al., 1994; Nesbit et al., 2004).
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Short Communication
We present here the first Brazilian case of HDR syn-
drome. A European descendant family from the southern
region of Brazil presented three individuals diagnosed with
hearing loss of unknown etiology (Figure 1A). Of these, the
proband (III:2) and his mother (II:2) were diagnosed early
in life with bilateral moderate to severe sensorineural hear-
ing loss and both have been using hearing aids since. Fur-
thermore, their hearing loss is non-progressive according to
regular audiological evaluations. On the other hand, the
maternal grandfather of the proband (I:1) was diagnosed
with normal hearing in low frequencies, but with a slope
representing severe bilateral hearing loss at 4KHz, after
which there is a slight improvement of hearing at 8KHz
(Figure 1B). This, together with the fact that the hearing
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Figure 1 - Results of the analyzed family. A) Pedigree of the studied family with the genetic screening for the p.Arg367* mutation in the GATA3 gene.
For the individual II:2, the square denoting other clinical manifestations is marked due to her bicuspid aortic valve. B) Audiograms of the three affected
members of the family. Individual I:1 (74 years old) presented normal hearing in low frequencies and a bilateral slope at 4KHz, with an improvement in
hearing at 8KHz. The II:2 (37 years old) and III:2 (4 years old) presented bilateral sensorineural moderate to severe hearing loss. C) Electropherograms of
the proband (III:2), his mother (II:2) and his grandparents (I:1 and I:2), which indicate a case of de novo mutation in the mother of the proband.
loss of individual I:1 started when he was around 50 years
old, exclude the possibility of presbycusis. Moreover, the
audiological exams performed at the age of 74 shows a pat-
tern that is typical for noise-induced hearing loss. Audio-
logical tests confirmed normal hearing for the remaining
family members.
Genomic DNA extracted from blood samples of all
family members was subjected to primary molecular
screening of mutations in the GJB2 gene, deletions in the
GJB6 gene and the mitochondrial mutation m.A1555G, but
no alterations were detected. However, whole exome se-
quencing (WES) of the proband (III:2) identified a hetero-
zygous c.1099C > T mutation (p.Arg367*) in the GATA3
gene, which was confirmed by Sanger sequencing. The
segregation analysis in the family revealed the presence of
this mutation in the mother of the proband (II:2), but not in
any of his maternal grandparents, despite the hearing prob-
lem of his grandfather (I:1) (Figure 1C). The same molecu-
lar results were obtained in repeated tests on a new blood
aliquot from the individuals. Nine different human poly-
morphic markers (D8S1179, D3S1358, D5S818, D7S820,
D18S51, FGA, CSF1PO, TH01, D21S11) were genotyped
in the I:1, I:2, II:1 and II:2 individuals in order to verify if
I:1 and I:2 are the progenitors of II:1 and II:2. This con-
firmed the paternity of individual II:2 and verified
p.Arg367* as a de novo mutation in the mother of the
proband, as well as the segregation of this mutation to the
proband. The mutation frequency was checked using the
Brazilian Initiative on Precision Medicine (BIPMed) and
the Online Archive of Brazilian Mutations (ABraOM) da-
tabases, which both lacked information about the mutation
in their 1430 analyzed chromosomes (for details of material
and methods see Mat-Met S1 and Table S1 in Supplemen-
tary Material). All molecular tests were done in the Human
Molecular Genetics laboratory at the Center of Molecular
Biology and Genetic Engineering (UNICAMP, Brazil) af-
ter all individuals agreed and signed the terms of consent
containing all information about the research. The study
was approved by the Research Ethics Committee of the
Faculty of Medical Sciences of UNICAMP (Process no.
396/2006).
Due to the relationship between the p.Arg367* muta-
tion and the HDR syndrome, an additional investigation re-
garding hypoparathyroidism and renal abnormalities was
conducted and detailed anamneses were remade. The pro-
band presented normal levels of calcium (9.2 mg/dL, nor-
mal range: 8.8-11 mg/dL), PTH (12 pg/mL, normal range:
4-58 pg/mL) and phosphate (4.9 mg/dL, normal child ran-
ge: 4-7 mg/dL). Similarly, the mother (II:2) also presented
normal levels for all exams (calcium: 9 mg/dL, normal
range: 8.8-11 mg/dL; PTH: 19 pg/mL, normal range: 4-58
pg/mL; phosphate: 4.1 mg/dL, normal adult range: 2.5-5.6
mg/dL). This excluded the presence of hypoparathyroidism
in both the proband and his mother.
Regarding renal abnormalities, the proband was diag-
nosed with right renal agenesis while intrauterine; how-
ever, this was never associated to his hearing loss or to a
syndrome. Furthermore, the mother has had kidney stones
since the age of 33, but neither the proband nor his mother
presented proteinuria or hematuria in new blood tests. Nev-
ertheless, it can be concluded that at least the proband has
renal abnormalities and, therefore, presents another HDR
syndrome clinical manifestation in addition to the hearing
loss.
In fact, the HDR syndrome has a very heterogeneous
phenotype that varies even within a family with the same
mutation. Ferraris et al. (2009) studied the HDR clinical
manifestations in 77 patients, and found that 62.3% pre-
sented hypoparathyroidism, deafness and renal abnormali-
ties, while 28.6% presented only hypoparathyroidism and
deafness. Deafness coupled with renal abnormalities con-
stituted only 2.6% of the cases, which is the case for the
family in our study.
The p.Arg367* mutation identified in the proband in
this study results in a premature stop codon, thereby short-
ening the GATA3 protein by 77 amino acids. The mutation
occurs after the ZnF2 domain, but is predicted to delete the
C-terminal part of the protein, which is essential for DNA
binding (Omichinski et al., 1993; Van Esch et al., 2000;
Nesbit et al., 2004). The mutation was first reported in an
individual from a Japanese family (Muroya et al., 2001).
The variant was not present in the parents or the sister, indi-
cating a de novo mutation in the proband. All three symp-
toms were present in the proband, while her daughter
inherited the mutation, but with sensorineural deafness as
the only symptom. Another study found the same mutation
in a family from Northern Europe, of which one individual
presented hypoparathyroidism and deafness without any
renal problems. None of the parents had the mutation and,
hence, this was a case of the same de novo mutation (Nesbit
et al., 2004). Furthermore, two children in a Chinese family
were clinically diagnosed with HDR syndrome and both
were heterozygous for the p.Arg367* mutation with hypo-
parathyroidism and deafness as symptoms. Again, none of
the parents had the mutation and the paternity was further
confirmed by tests using four polymorphic markers, which
lead to a final hypothesis that the mutation was caused by
germinal mosaicism (Sun et al., 2009). The latest report of
HDR syndrome caused by the p.Arg367* mutation in the
GATA3 gene is a male infant from a Turkish family, who
presented hypoparathyroidism and renal anomalies, while
auditory tests were normal. This was also classified as a de
novo mutation, since it was not found in the parents of the
proband (Döneray et al., 2015) (Table 1).
To our knowledge, there are no studies regarding the
frequency of HDR syndrome in the world population, but it
can be considered as a rare disorder (Van Beelen et al.,
2014). Regarding the HDR syndrome caused by the
p.Arg367* mutation, our study represents the sixth re-
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ported case and the first one on the American continent.
Our analyses concluded that the hearing loss in the studied
family was not non-syndromic as first suspected, but rather
the result of the HDR syndrome. These findings are sup-
ported by the occurrence of the p.Arg367* mutation in the
GATA3 gene in the proband and his mother. Importantly,
the proband in our study was diagnosed with deafness and
renal abnormalities, which is the first report of these two
symptoms as the only clinical manifestations caused by the
p.Arg367* mutation, thereby confirming the high pheno-
type heterogeneity associated with this syndrome. Despite
the same genotype, the symptoms vary between individual
II:2 with only sensorineural hearing loss and individual
III:2 with both hearing loss and renal abnormalities, which
is well in accordance with the heterogeneity aspect. Fur-
thermore, this study, together with the studies of the Turk-
ish and Northern Europe families, contradicts the belief that
the p.Arg367* mutation is exclusively found in Far East
populations (Nesbit et al., 2004; Döneray et al., 2015;).
The results presented here also show how molecular
diagnostic can aid the correct clinical diagnosis of affected
individuals. Proper and complete diagnosis of a condition,
coupled to efficient genetic counseling, can prevent an in-
fant from developing more severe symptoms in adult life,
since the chances of correct treatment and the ability to an-
ticipate medical problems are markedly increased. Hence, a
decrease of patient life quality can be counteracted and pos-
sibly even prevented. In the case of HDR syndrome, the
clinical heterogeneity makes screening of the GATA3 gene
both important and worthwhile in suspected cases.
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